Global Calcitonin Gene-Related Peptide Receptor Antagonist Market Segmentation, By Drug Type (Zavegepant, Ubrogepant, Olcegepant, Telcegepant, Rimegepant, and Others), Application (Migraine, Osteoarthritis, and Others), Dosage (Tablet and Others), Route of Administration (Oral, Sublingual, and Other), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2031
Calcitonin Gene-Related Peptide Receptor Antagonist Market Analysis
Calcitonin gene-related peptide receptor antagonists (CGRP-RAs), such as rimegepant and ubrogepant, show promise in migraine treatment. Recent advancements include improved bioavailability and fewer side effects. Cutting-edge methods such as monoclonal antibodies enhance targeting precision. This technology's growth is driven by increased migraine prevalence and patient demand for non-opioid options, revolutionizing chronic pain management.
Calcitonin Gene-Related Peptide Receptor Antagonist Market Size
The global calcitonin gene-related peptide receptor antagonist market size was valued at USD 3.06 billion in 2023 and is projected to reach USD 6.92 billion by 2031, with a CAGR of 10.73% during the forecast period 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Type (Zavegepant, Ubrogepant, Olcegepant, Telcegepant, Rimegepant, and Others), Application (Migraine, Osteoarthritis, and Others), Dosage (Tablet and Others), Route of Administration (Oral, Sublingual, and Other), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Bristol-Myers Squibb Company (U.S.), Biohaven, Ltd. (U.S.), AbbVie Inc. (Ireland), Merck & Co., Inc. (U.S.), Boehringer Ingelheim International GmbH (Germany), and Biosynth Carbosynth (U.K.)
|
|
Market Opportunities
|
|
Calcitonin Gene-Related Peptide Receptor Antagonist Market Definition
A calcitonin gene-related peptide (CGRP) receptor antagonist is a type of medication that blocks the action of CGRP, a neuropeptide involved in pain transmission and inflammation. By inhibiting CGRP receptors, these drugs are used to treat migraine headaches by reducing vasodilation and neurogenic inflammation in the brain. They offer relief by targeting specific pathways implicated in migraine pathophysiology.
Global Autoimmune Disease Diagnosis Market Dynamics
Drivers
- Rising Incidence of Migraine Disorders
The rising global prevalence of migraine disorders is a significant driver for the CGRP receptor antagonist market. As more individuals experience debilitating migraines, there is a growing demand of calcitonin gene related peptide receptor antagonists for migraine effective treatments. CGRP receptor antagonists, such as erenumab and fremanezumab, are tailored to specifically target the pathways involved in migraine attacks. This targeted approach not only enhances treatment efficacy but also propels market growth by addressing a critical unmet medical need in neurological care.
- Advancements in Drug Delivery
Government initiatives aimed at enhancing healthcare infrastructure and advocating for early diagnosis and treatment of autoimmune diseases stimulate market growth by increasing access to diagnostic services and treatment options. Such initiatives foster a conducive environment for the development and adoption of innovative diagnostic technologies, driving market expansion.
Opportunities
- Advancements in Drug Delivery
Advancements in drug delivery methods, such as oral tablets and injectables, are transforming the CGRP receptor antagonist market by improving patient convenience and compliance. For instance, the development of once-monthly injectable formulations reduces treatment frequency and enhances adherence. Similarly, oral tablet formulations offer non-invasive administration options. These innovations not only broaden treatment options but also address patient preferences, driving market opportunities and expanding access to effective migraine therapies.
- Increasing Demand for Personalized Medicine
The increasing demand for personalized medicine in neurology is driving the growth of the CGRP receptor antagonist market. Tailored treatment approaches cater to individual patient needs, enhancing efficacy and patient outcomes. For instance, pharmaceutical companies are developing CGRP receptor antagonists that target specific molecular pathways implicated in migraines, offering personalized treatment options. This trend not only improves patient satisfaction but also expands the market by meeting diverse therapeutic needs in neurology.
Restraints/Challenges
- Competition from Established Therapies
Competition from established therapies such as triptans and NSAIDs presents a significant barrier for CGRP receptor antagonists in the migraine management market. Convincing healthcare providers and patients to switch to these newer treatments is challenging without clear evidence of superior efficacy or fewer side effects. This hurdle complicates market penetration and adoption despite potential advantages of CGRP receptor antagonists.
- High Development Costs
High development costs for CGRP receptor antagonists, encompassing extensive research, clinical trials, and regulatory filings, pose a significant deterrent for pharmaceutical companies. These financial barriers can impede investment in the market, limiting the availability of new treatments and potentially slowing down innovation in migraine therapy.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Calcitonin Gene-Related Peptide Receptor Antagonist Market Scope
The market is segmented on the basis of type, application, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Type
- Zavegepant
- Ubrogepant
- Olcegepant
- Telcegepant
- Rimegepant
- Others
Application
- Migraine
- Osteoarthritis
- Others
Dosage
- Tablet
- Others
Route of Administration
- Oral
- Sublingual
- Other
End-Users
- Clinic
- Hospital
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Calcitonin Gene-Related Peptide Receptor Antagonist Market Regional Analysis
The market is analysed and market size insights and trends are provided by country, type, application, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to dominate the calcitonin gene-related peptide receptor antagonist market, fueled by major key players, high disposable income, a well-developed healthcare sector, and high drug costs in the region. These factors consolidate its position as a pivotal market for CGRP receptor antagonists.
Asia-Pacific is expected to grow in the calcitonin gene-related peptide receptor antagonist market due to increasing research and development activities, emerging markets, rising investment in healthcare, and growing government support. These factors are set to drive market expansion during the forecast period, reflecting a robust growth trajectory in the region.
The Asia-Pacific region exhibits the fastest-growing compound annual growth rate (CAGR) in the forecast period, driven by a burgeoning geriatric population. This demographic trend correlates with a rise in chronic disease incidences across the region, emphasizing the pressing need for improved healthcare infrastructure and disease management strategies.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Calcitonin Gene-Related Peptide Receptor Antagonist Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Some of the major players operating in the market are:
- Bristol-Myers Squibb Company (U.S.)
- Biohaven, Ltd. (U.S.)
- AbbVie Inc. (Ireland)
- Merck & Co., Inc. (U.S.)
- Boehringer Ingelheim International GmbH (Germany)
- Biosynth Carbosynth (U.K.)
SKU-